Canada's Cardiome chooses Medicon A/S to conduct heart drug trials  

Cardiome Pharma Corp chooses Denmark's Medicon A/S to carry out international drug studies of the anti-arrhythmic agent RSD1235

Canadian biopharmaceutical company Cardiome (Cardiome Pharma Corp.) has chosen Copenhagen based Medicon A/S to carry out two large international drug studies with Cardiome’s anti-arrhythmic agent RSD1235. A total of 420 patients will participate in the studies which will take place at hospital sites in the US, Canada and Scandinavia.

Cardiome is a cardiovascular drug development company based in British Columbia. It currently has three late stage clinical drug programmes focused on atrial arrhythmias, congestive heart failure and hyperuricemia (gout). Medicon is a drug development company founded in 1985 which offers academic and operational services in drug development phases I-IV. The news is reported by and on Medicon’s website.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×